• Alethia Biotherapeutics Inc., of Montreal, was granted U.S. Patent No. 7,947,436, titled "Polynucleotide and Polypeptide Sequences Involved in the Process of Bone Remodeling." It provides protection for identification of Tsp50 inhibitors of osteoclast differentiation.

• Alvine Pharmaceuticals Inc., of San Carlos, Calif., received U.S. Patent Nos. 7,943,312; 7,928,056; 7,923,532; and 7,910,541, which protect various aspects of the company's core technology, including gluten degradation with gluten-specific proteases, methods for identifying proteases useful in degrading gluten and reagents for diagnosing celiac disease. The patents are licensed from Stanford University.

• Anadys Pharmaceuticals Inc., of San Diego, received U.S. Patent No. 7,939,524, covering setrobuvir (ANA598), its direct-acting antiviral in Phase IIb development for chronic hepatitis C virus.

• AVI BioPharma Inc., of Bothell, Wash., was granted U.S. Patent No. 7,943,762, titled "Oligonucleotide Analogs Having Cationic Intersubunit Linkages," which covers composition of matter for its advanced generation of phosphorodiamidate morpholino oligonucleotide chemistry called PMOplus.

• Biomoda Inc., of Albuquerque, N.M., received a notice of allowance for a patent expanding the use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

• BioTime Inc., of Alameda, Calif., was granted U.S. Patent No. 7,928,069, covering aspects of the composition of Glycosan hydrogels.

• Cell Biosciences Inc., of Santa Clara, Calif., received U.S. Patent No. 7,935,489, along with 7,935,308 and 7,935,479, addressing central aspects of the firm's NanoPro assay technology.

• Cleveland BioLabs Inc., of Buffalo, N.Y., received a notice of allowance for a patent, titled "Flagellin Related Polypeptides and Uses Thereof," which covers composition of matter and use of CBLB502 for protecting a mammal from radiation.

• Convergen Life Sciences, of Austin, Texas, received a patent covering CNVN202, a targeted molecular therapy in clinical testing in lung cancer.

• Cortex Pharmaceuticals Inc., of Irvine, Calif., received a notice of allowance for a patent protecting lead Ampakine molecule CX1739. The patent is titled "Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses" and covers the third-generation low impact Ampakine compound.

No Comments